Pemivibart Explained
| Type: | mab |
| Mab Type: | mab |
| Source: | u |
| Target: | Spike protein of SARS-CoV-2 |
| Tradename: | Pemgarda |
| Dailymedid: | Pemivibart |
| Routes Of Administration: | Intravenous |
| Atc Prefix: | None |
| Legal Us: | Rx-only |
| Legal Us Comment: | via EUA[1] [2] |
| Cas Number: | 2858673-18-2 |
| Unii: | 557S3L3FAP |
| Kegg: | D12876 |
| Synonyms: | VYD222 |
Pemivibart, sold under the brand name Pemgarda, is a monoclonal antibody medication authorized for the pre-exposure prophylaxis (prevention) of COVID19.
The US Food and Drug Administration (FDA) issued an emergency use authorization for pemivibart in March 2024.[3] [4]
Medical uses
In the US, pemivibart is authorized for the pre-exposure prophylaxis (prevention) of COVID19 in certain adults and adolescents (12 years of age and older weighing at least 40kg (90lb). It is authorized for individuals who are not currently infected with SARSCoV2 and who have not had a known recent exposure to an individual infected with SARSCoV2; and who have moderate-to-severe immune compromise due to a medical condition or due to taking immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID19 vaccination.
Society and culture
Names
Pemivibart is the international nonproprietary name.[5]
Notes and References
- Web site: Emergency Use Authorization: PEMGARDA (pemivibart) . 22 March 2024 . U.S. Food and Drug Administration .
- Web site: Highlight of Emergency Use Authorization: PEMGARDA (pemivibart) . U.S. Food and Drug Administration . 23 March 2024 . 23 March 2024 . https://web.archive.org/web/20240323211217/https://www.fda.gov/media/177067/download . live .
- Web site: FDA Roundup: March 22, 2024 . U.S. Food and Drug Administration (FDA) . 22 March 2024 . 23 March 2024 . 23 March 2024 . https://web.archive.org/web/20240323211210/https://www.fda.gov/news-events/press-announcements/fda-roundup-march-22-2024 . live .
- Invivyd Announces FDA Authorization for Emergency Use of Pemgarda (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19 . Invivyd . GlobeNewswire . 22 March 2024 . 23 March 2024 . 23 March 2024 . https://web.archive.org/web/20240323211051/https://www.globenewswire.com/news-release/2024/03/22/2851117/0/en/Invivyd-Announces-FDA-Authorization-for-Emergency-Use-of-PEMGARDA-Formerly-VYD222-for-Pre-exposure-Prophylaxis-PrEP-of-COVID-19.html . live .
- ((World Health Organization)) . INN Proposed International Nonproprietary Names: List 129 . WHO Drug Information . 37 . 2 . 265–571 . 2023 . 10665/371789 . free .
